Skip to main content

Table 3 Rosiglitazone pharmacokinetic parameters by SLCO1B1 diplotype group

From: Influence of SLCO1B1 and CYP2C8gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

Pharmacokinetic parameter

Group 1 (*1A/*1A) n= 6

Group 2 (*1A/*1B or *1B/*1B) n= 7

Group 3 (*5, *15, *16, or *17 haplotype carriers) n= 13

pvalue

AUC0-∞ (ng*h/ml)

1601 ± 451 (1128, 2074)

2019 ± 624 (1442, 2595)

1699 ± 417 (1447, 1951)

0.26

CL/F (ml/h)

2673 ± 766 (1869, 3477)

2153 ± 673 (1530, 2775)

2495 ± 633 (2112, 2877)

0.37

CL/F/kg (ml/h/kg)

40.9 ± 9.4 (31, 50.8)

33 ± 9.2 (24.5, 41.5)

37.5 ± 10 (31.5, 43.6)

0.35

t1/2 (h)

4.1 ± 0.9 (3.2, 5)

3.9 ± 0.8 (3.2, 4.7)

3.8 ± 0.8 (3.3, 4.3)

0.78

Cmax (ng/ml)

337 ± 125 (206, 469)

409 ± 86 (329, 489)

383 ± 113 (315, 451)

0.50

Tmax (hr)

1.0 ± 0.6 (0.4, 1.6)

0.8 ± 0.4 (0.4, 1.2)

0.9 ± 0.5 (0.7, 1.2)

0.68

  1. Data are presented as mean ± SD, along with 95% confidence intervals. Abbreviations: AUC, area under the plasma concentration-time curve; CL/F, apparent oral clearance; CL/F/kg, weight-adjusted oral clearance; t1/2, half-life; Cmax, maximum plasma concentration; Tmax, time to maximum plasma concentration.